智通财经APP讯，上海家化(600315.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净 利润2.4亿元到2.9亿元，与上年同期(法定披露数据)相比，将实现扭亏为盈。 ...

上海家化（600315）(600315.SH)发布公告，公司预计2025年年度实现归属于母公司所有者的净利润2.4 亿元到2.9亿元，与上年同期(法定披露数据)相比，将实现扭亏为盈。 ...

格隆汇1月28日丨上海家化(600315.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润2.4亿元到2.9亿元，与上年同期(法定披露数据)相比，将实现扭亏为盈。预计2025年年 度实现归属于母公司所有者的扣除非经常性损益后的净利润3800万元到5600万元。 本期业绩预盈的主要原因为：(一)主营业务影响：2025年公司贯彻执行"四个聚焦"的经营战略，加强品 牌营销，主营业务收入实现增长；产品结构优化使得毛利率提升。(二)非经营性损益的影响：2025年度 公司持有的金融资产公允价值变动损益以及投资收益增加。 ...

本期业绩预盈的主要原因为：(一)主营业务影响：2025年公司贯彻执行"四个聚焦"的经营战略，加强品 牌营销，主营业务收入实现增长；产品结构优化使得毛利率提升。(二)非经营性损益的影响：2025年度 公司持有的金融资产公允价值变动损益以及投资收益增加。 格隆汇1月28日丨上海家化(600315.SH)公布，经财务部门初步测算，预计2025年年度实现归属于母公司 所有者的净利润2.4亿元到2.9亿元，与上年同期(法定披露数据)相比，将实现扭亏为盈。预计2025年年 度实现归属于母公司所有者的扣除非经常性损益后的净利润3800万元到5600万元。 ...

证券代码：600315 证券简称：上海家化 公告编号：临 2026-001 上海家化联合股份有限公司 2025 年年度业绩预盈公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：净利润实现扭亏为盈。 业绩预告相关的主要财务数据情况：经财务部门初步测 算，预计 2025 年年度实现归属于母公司所有者的净利润 2.4 亿元到 2.9 亿元，与上年同期（法定披露数据）相比， 将实现扭亏为盈。 预计2025年年度实现归属于母公司所有者的扣除非经常 性损益后的净利润 3800 万元到 5600 万元。 一、本期业绩预告情况 （一）业绩预告期间：2025 年度 （二）业绩预告情况 经财务部门初步测算，预计 2025 年年度实现归属于母公司 所有者的净利润 2.4 亿元到 2.9 亿元，与上年同期（法定披露数 据）相比，将实现扭亏为盈。 预计 2025 年年度实现归属于母公司所有者的扣除非经常性 损益后的净利润 3800 万元到 5600 万元。 二、上年同期经营业绩和财务状况 （一）利润总额：-8 ...

Core Viewpoint - Shanghai Jahwa announced an expected net profit attributable to the parent company of 240 million to 290 million yuan for the year 2025, indicating a turnaround from loss to profit compared to the same period last year [1] Group 1 - The company will implement a "four focuses" business strategy in 2025 [1] - Strengthening brand marketing is a key component of the company's strategy [1] - The main business revenue is expected to grow due to the execution of the new strategy [1] Group 2 - Product structure optimization is anticipated to enhance the gross profit margin [1]

Investment Rating - The report rates the cosmetics and medical beauty industry as "Overweight" for 2025, indicating an expectation for the industry to outperform the overall market [2][11]. Core Insights - The demand side of the cosmetics and medical beauty sector is expected to accelerate, with retail sales of cosmetics projected to reach 465.3 billion yuan in 2025, a year-on-year growth of 5.1%, surpassing the overall retail growth by 1.4 percentage points [3]. - The performance of Hong Kong-listed beauty companies is strong, with significant growth in GMV (Gross Merchandise Volume) through platforms like Douyin, particularly during promotional events like Double Eleven [3]. - The A-share market shows a mixed performance, with companies like Ruoyuchen and Shanghai Jahwa experiencing substantial improvements in their earnings [3]. - The e-commerce operation sector is rebounding, with companies like Ruoyuchen and Yiwang Yichuang expected to see profit growth exceeding 50% in 2025 [3]. - The medical beauty segment is anticipated to face slight fatigue due to macroeconomic factors, but new product launches are expected to stimulate consumer interest in 2026 [3]. Summary by Sections Cosmetics Sector - Retail sales of cosmetics are projected to grow by 5.1% in 2025, with Q4 growth reaching 9.9% [3]. - Key companies such as Shiseido and Lin Qingxuan are expected to see significant GMV growth, with Lin Qingxuan projected to achieve triple-digit growth [3]. - Investment recommendations include companies with strong channel and brand matrices like Maogeping, Shiseido, and Lin Qingxuan, as well as those with improving earnings like Porlaia and Marubi [3]. Medical Beauty Sector - The medical beauty sector is expected to be impacted by macroeconomic conditions, with companies like Aimeike facing challenges [3]. - Recommendations focus on companies with strong R&D capabilities and broad product pipelines, such as Aimeike and Langzi [3]. E-commerce and Operations - The e-commerce operation sector is recovering, with companies like Ruoyuchen and Qingmu Technology expected to see significant profit growth [3]. - The report highlights the importance of self-operated brands and the potential for high growth in this segment [3]. Key Company Valuations - The report provides a valuation table for key companies, indicating a "Buy" rating for several firms including Porlaia, Maogeping, and Shiseido, with projected PE ratios reflecting growth expectations [5].

【文/王力 编辑/周远方】 在效率至上、利润优先的商业世界里，一个根本性问题常被搁置：基于严谨科学、能真实改善生活的产品，其价值是否必然与高昂价格绑定？2026年初，于 河北金山岭长城脚下，上海家化旗下医学护肤品牌玉泽，用其23年的历程给出了坚定而温暖的答案。 这一答案的源头，需回溯至23年前。上海家化与瑞金医院皮肤科开启了一项看似"反效率"的合作。历经六年研发与上千例临床验证后，在定价的关键时刻， 上海交通大学医学院附属瑞金医院终身教授、玉泽首席科学家郑捷基于临床中对皮肤患者真实处境的深刻理解，坚决主张：医学护肤应服务于真正的皮肤健 康需求，是"雪中送炭"，而非"锦上添花"。也正是这一坚定选择，为品牌奠定了坚实的价值根基——产品的意义，不止于功效，更在于被真正需要的人所信 赖与使用。 而今最初的承诺已生长为坚实的体系。通过设立专项慈善基金形成"公益+科研"闭环，累计完成超5000例临床研究，并与全国40余家顶尖医院持续合作，玉 泽构筑起一道独特的"医研长城"。从最新推出的特润霜，到同步发布的《国民皮肤屏障健康绿宝书》，玉泽始终在践行同一个使命：让基于实证的医学护 肤，真正从实验室走向千家万户百姓，守护千万人 ...

Market Overview - The cosmetics sector experienced a decline of 1.27% on January 27, with Marubi Biotechnology leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Key performers in the cosmetics sector included: - Jiahen Home Cosmetics (300955) with a closing price of 41.47, up 6.88% and a trading volume of 73,900 shares, totaling 303 million yuan [1] - Qingdao Kingway (002094) closed at 8.24, up 3.00% with a trading volume of 569,900 shares, totaling 467 million yuan [1] - Conversely, Marubi Biotechnology (603983) closed at 31.84, down 4.47% with a trading volume of 46,400 shares, totaling 149 million yuan [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 43.98 million yuan from main funds, while retail investors contributed a net inflow of 43.99 million yuan [2] - Notable capital flows included: - Qingdao Kingway (002094) with a net inflow of 22.70 million yuan from main funds [3] - Shanghai Jahwa (600315) with a net inflow of 8.10 million yuan from main funds [3] - Marubi Biotechnology (603983) experienced a slight net outflow of 94,800 yuan from main funds [3]

新华财经上海1月27日电 "皮肤是抵御外来病原体入侵的第一道防线，是人体的'动态长城'。" "多数情况下，敏感肌都是后天形成的。""修护皮肤屏障不是缺 什么补什么，而是要激活自身修复能力"……日前在玉泽新品发布会上，上海交通大学医学院附属瑞金医院终身教授郑捷、美国加州大学旧金山分校皮肤医 学专家蔄茂强等多位专家学者现场"上课"。专家的讲解，让前沿的皮肤科学理论，不再那么晦涩难懂、遥不可及。同时，医研共创也让这些科研成果从专 利、论文变成市场上的畅销产品。 近年来，医研共创成为国内外化妆品巨头构建差异化优势的战略选择之一。欧莱雅增资制药公司高德美，同年官宣与华山医院共建"皮肤科学实验室"；日妆 巨头资生堂加码中国医美市场，与上海九院等医疗机构展开科研合作；雅诗兰黛集团与嘉会医疗在沪设立联合临床研究中心……一系列动作表明，行业竞争 正从"博流量"转向对基础研究、临床验证和跨学科转化能力的比拼。 "买得起、用得久"饱含医者匠心 "我倡导'健康皮肤、美丽皮肤、健康身体'的理念，皮肤作为人体最大的器官，脱离健康去谈美丽是没意义的。"郑捷说。 美丽建立在健康之上。从医学角度看，维护皮肤屏障的健康对于预防皮肤疾病、保持皮肤 ...